Drug Profile


Alternative Names: Lucanthone hydrochloride; Tixantone

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Albert Einstein College of Medicine
  • Developer Spectrum Pharmaceuticals; University of Alabama at Birmingham
  • Class Antineoplastics; Antiparasitics; Radiosensitisers; Small molecules; Thioxanthenes; Xanthones
  • Mechanism of Action DNA apurinic apyrimidinic site lyase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain metastases; Breast cancer; Glioblastoma

Most Recent Events

  • 10 Aug 2015 The University of Alabama at Birmingham and Spectrum Pharmaceuticals suspend a phase II trial in Brain metastases (Adjunctive treatment) in USA, as the principal investigator left the university (PO) (NCT02014545)
  • 30 Nov 2013 Phase-II clinical trials in Brain metastases in USA (PO)
  • 30 Oct 2013 Discontinued - Phase-II for Glioblastoma in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top